![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/e/e1/Niraparib.svg/640px-Niraparib.svg.png&w=640&q=50)
Niraparib
Anti-cancer medication / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Niraparib?
Summarize this article for a 10 year old
Niraparib, sold under the brand name Zejula, is an anti-cancer medication used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer.[3][4][5] It is taken by mouth.[3][4] It is a PARP inhibitor.
![]() | |
Clinical data | |
---|---|
Pronunciation | /nɪˈræpərɪb/ nih-RAP-uh-rib |
Trade names | Zejula |
Other names | MK-4827 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a617007 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 73% |
Protein binding | 83% |
Metabolism | Carboxylesterases |
Metabolites | M1 (carboxylic acid) |
Elimination half-life | 36 hours |
Excretion | 48% urine, 29% feces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.210.548 ![]() |
Chemical and physical data | |
Formula | C19H20N4O |
Molar mass | 320.396 g·mol−1 |
3D model (JSmol) | |
Solubility in water | 0.7–1.1 |
| |
|
The most common side effects include nausea (feeling sick), thrombocytopenia (low blood platelet counts), tiredness and weakness, anemia (low red blood cell counts), constipation, vomiting, abdominal (belly) pain, neutropenia (low levels of neutrophils, a type of white blood cell), insomnia (difficulty sleeping), headache, lack of appetite, diarrhea, dyspnea (difficulty breathing), hypertension (high blood pressure), back pain, dizziness, cough, joint pain, hot flushes and decrease in white blood cells.[4]
Niraparib was approved for medical use in the United States and in the European Union in 2017.[4][6][7]